Josef S Smolen

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text

Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

Ravinder N. Maini, Peter C. Taylor, Jacek Szechiński et al. · Arthritis & Rheumatism · 2006 · 789 citations

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine

Peter Valent, Bernd Groner, Udo Schumacher et al. · Journal of Innate Immunity · 2016 · 403 citations · Full text

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Josef S Smolen, Paul Emery, Roy Fleischmann et al. · The Lancet · 2013 · 272 citations

Rheumatoid Disorder, Rheumatology, Medicine +7

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients

Daniel Aletaha, Julia Funovits, Edward Keystone et al. · Arthritis & Rheumatism · 2007 · 261 citations